DURECT Corp banner

DURECT Corp
NASDAQ:DRRX

Watchlist Manager
DURECT Corp Logo
DURECT Corp
NASDAQ:DRRX
Watchlist
Price: 1.91 USD -1.04% Market Closed
Market Cap: $59.3m

DURECT Corp
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

DURECT Corp
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
DURECT Corp
NASDAQ:DRRX
Inventory
$291k
CAGR 3-Years
-48%
CAGR 5-Years
-39%
CAGR 10-Years
-23%
Johnson & Johnson
NYSE:JNJ
Inventory
$14.2B
CAGR 3-Years
4%
CAGR 5-Years
9%
CAGR 10-Years
6%
Bristol-Myers Squibb Co
NYSE:BMY
Inventory
$2.7B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
8%
Pfizer Inc
NYSE:PFE
Inventory
$10.7B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Merck & Co Inc
NYSE:MRK
Inventory
$6.7B
CAGR 3-Years
4%
CAGR 5-Years
1%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Inventory
$13.7B
CAGR 3-Years
47%
CAGR 5-Years
28%
CAGR 10-Years
15%
No Stocks Found

DURECT Corp
Glance View

Market Cap
59.3m USD
Industry
Pharmaceuticals

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 79 full-time employees. The company went IPO on 2000-09-28. The firm's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The firm is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with severe alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The firm focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug.

DRRX Intrinsic Value
9.97 USD
Undervaluation 81%
Intrinsic Value
Price

See Also

What is DURECT Corp's Inventory?
Inventory
291k USD

Based on the financial report for Jun 30, 2025, DURECT Corp's Inventory amounts to 291k USD.

What is DURECT Corp's Inventory growth rate?
Inventory CAGR 10Y
-23%

Over the last year, the Inventory growth was -88%. The average annual Inventory growth rates for DURECT Corp have been -48% over the past three years , -39% over the past five years , and -23% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett